文献速递呼吸道感染呼吸危重症与机械通气

重症至危重症COVID-19后呼吸恢复轨迹:1年前瞻性多中心研究

Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study.
PubMed 文献 · Eur Respir J · 2023-04-01

本研究前瞻性随访485例重症至危重症COVID-19住院幸存者至出院后12个月,评估肺功能与影像学恢复轨迹。3个月时34%有限制性通气障碍、70%弥散功能受损、56%有显著影像学后遗症;DLCO与FVC%预计值在6个月和12个月分别改善约4点和6点,但41%患者末次CT仍有显著后遗症。

要点

  • 重症COVID-19幸存者3个月时弥散功能受损达70%,限制性通气障碍34%。
  • DLCO与FVC%预计值至12个月分别改善约4点和6点,但部分患者残留后遗症。
  • 41%患者末次CT仍有显著后遗症,标准氧疗者亦不少见,需延长随访。

核心结论

  • 重症至危重症COVID-19后肺功能与影像学异常至1年仍有改善,但显著肺后遗症和残留症状比例高,需延长随访。

研究设计与样本

  • 前瞻性多中心队列研究,纳入485例因重症至危重症COVID-19住院的成人,在出院后3个月至12个月评估。

主要发现

  • 3个月时34%有限制性肺缺陷,70%弥散功能(DLCO)受损,56%有显著影像学后遗症。
  • DLCO与FVC%预计值在6个月增加约4点、12个月增加约6点。
  • 475例(98%)随访中至少一次胸部CT,196例(41%)末次影像有显著后遗症。
  • 性别、BMI、慢性呼吸病、免疫抑制、肺炎范围、急性期糖皮质激素使用及延长有创机械通气与3个月DLCO相关,但与后续轨迹无关。

临床怎么用

  • 对重症至危重症COVID-19幸存者应延长呼吸随访,重点关注DLCO、FVC和胸部影像。
  • 标准氧疗患者也可能出现显著肺后遗症,不应仅随访机械通气患者。

局限性

  • 6个月和12个月再评估比例分别为60%和35%,失访率较高。
  • 标准氧疗亚组再评估比例更低(6个月51%、12个月27%),可能影响代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survivors of severe-to-critical coronavirus disease 2019 (COVID-19) may have functional impairment, radiological sequelae and persistent symptoms requiring prolonged follow-up. This pragmatic study aimed to describe their clinical follow-up and determine their respiratory recovery trajectories, and the factors that could influence them and their health-related quality of life. METHODS: Adults hospitalised for severe-to-critical COVID-19 were evaluated at 3 months and up to 12 months post-hospital discharge in this prospective, multicentre, cohort study. RESULTS: Among 485 enrolled participants, 293 (60%) were reassessed at 6 months and 163 (35%) at 12 months; 89 (51%) and 47 (27%) of the 173 participants initially managed with standard oxygen were reassessed at 6 and 12 months, respectively. At 3 months, 34%, 70% and 56% of the participants had a restrictive lung defect, impaired diffusing capacity of the lung for carbon monoxide (D LCO) and significant radiological sequelae, respectively. During extended follow-up, both D LCO and forced vital capacity percentage predicted increased by means of +4 points at 6 months and +6 points at 12 months. Sex, body mass index, chronic respiratory disease, immunosuppression, pneumonia extent or corticosteroid use during acute COVID-19 and prolonged invasive mechanical ventilation (IMV) were associated with D LCO at 3 months, but not its trajectory thereafter. Among 475 (98%) patients with at least one chest computed tomography scan during follow-up, 196 (41%) had significant sequelae on their last images. CONCLUSIONS: Although pulmonary function and radiological abnormalities improved up to 1 year post-acute COVID-19, high percentages of severe-to-critical disease survivors, including a notable proportion of those managed with standard oxygen, had significant lung sequelae and residual symptoms justifying prolonged follow-up.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Schlemmer F, Valentin S, Boyer L, et al. Respiratory recovery trajectories after severe-to-critical COVID-19: a 1-year prospective multicentre study. Eur Respir J. 2023. PMID: 36669777. doi:10.1183/13993003.01532-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。